TMPRSS2 Correlated With Immune Infiltration Serves As a Prognostic Biomarker in Prostatic Adenocarcinoma: Implication for the COVID-2019

Overview

Journal Front Genet

Date 2020 Nov 16

PMID 33193689

Citations 4

Authors

Lianxiang Luo

Yushi Zheng

Mingyue Li

Xinjie Lin

Xiaodi Li

Xiaoling Li

Liao Cui

Hui Luo

Affiliations

Soon will be listed here.

Abstract

Type 2 transmembrane serine protease (TMPRSS2) is a new member of the serine proteases, and studies have shown that TMPRSS2 plays a role in the occurrence of prostate malignancies and is closely related to the occurrence of the coronavirus disease 2019 (COVID-19). However, the role of TMPRSS2 in prostatic adenocarcinoma (PRAD) remains largely unclear. To better explore its function in PRAD, we examined the expression level of TMPRSS2 in the GEO, tumor immune assessment resource (TIMER), as well as Oncomine databases and studied the association between TMPRSS2 and overall survival (OS) rates in the UALCAN and gene expression profiling interactive analysis (GEPIA) databases. In addition, we studied the correlation of the level of immune infiltration and markers of immune cell type in the TIMER database, analyzed the prognosis based on the expression level of TMPRSS2 in the related immune cell subsets, and determined the methylation profile of TMPRSS2 promoter by UALCAN database. Subsequently, we conducted a survival analysis and gene ontology (GO) pathway analysis in the TISID database and detected the expression of TMPRSS2 in the Human Protein Atlas (HPA) database. We also studied the protein-protein interaction (PPI) network of TMPRSS2 in the GENEMANIA database. Additionally, we used the microarray GSE56677 and GSE52920 to illustrate changes in TMPRSS2 expression and after severe acute respiratory syndrome-coronavirus (SARS-COV) infection, finding that expression of TMPRSS2 decreased after SARS-COV infection . The function of TMPRSS2 in the dataset was further verified by gene set enrichment analysis (GSEA). In conclusion, the expression of TMPRSS2 is significantly increased in PRAD, elevated TMPRSS2 is associated with immune infiltration, and prognosis is positively correlated. In addition, tumor tissue from COVID-19 patients with PRAD may be more susceptible to infection with SARS-COV-2, which may render the prognosis gets worse.

Citing Articles

COVID-19 and Prostatitis: A Review of Current Evidence.

Daneshwar D, Lee Y, Nordin A Diseases. 2024; 12(7).

PMID: 39057128 PMC: 11276594. DOI: 10.3390/diseases12070157.

TMPRSS2 is a tumor suppressor and its downregulation promotes antitumor immunity and immunotherapy response in lung adenocarcinoma.

Liu Z, Lu Q, Zhang Z, Feng Q, Wang X Respir Res. 2024; 25(1):238.

PMID: 38862975 PMC: 11167788. DOI: 10.1186/s12931-024-02870-7.

Multi-omics of the expression and clinical outcomes of TMPRSS2 in human various cancers: A potential therapeutic target for COVID-19.

Liu L, Qin J, Zuo M, Zhou Q J Cell Mol Med. 2021; 26(3):709-724.

PMID: 34951103 PMC: 8817140. DOI: 10.1111/jcmm.17090.

Luo L, Su J, Zheng Y, Huang F, Huang R, Luo H J Immunol Res. 2021; 2021:9938397.

PMID: 34604392 PMC: 8483904. DOI: 10.1155/2021/9938397.

References

Lu R, Zhao X, Li J, Niu P, Yang B, Wu H . Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020; 395(10224):565-574. PMC: 7159086. DOI: 10.1016/S0140-6736(20)30251-8. View

Uhlen M, Fagerberg L, Hallstrom B, Lindskog C, Oksvold P, Mardinoglu A . Proteomics. Tissue-based map of the human proteome. Science. 2015; 347(6220):1260419. DOI: 10.1126/science.1260419. View

Li T, Fan J, Wang B, Traugh N, Chen Q, Liu J . TIMER: A Web Server for Comprehensive Analysis of Tumor-Infiltrating Immune Cells. Cancer Res. 2017; 77(21):e108-e110. PMC: 6042652. DOI: 10.1158/0008-5472.CAN-17-0307. View

Parsons J, Gage W, Nelson W, De Marzo A . p63 protein expression is rare in prostate adenocarcinoma: implications for cancer diagnosis and carcinogenesis. Urology. 2001; 58(4):619-24. DOI: 10.1016/s0090-4295(01)01311-5. View

Smyth G, Michaud J, Scott H . Use of within-array replicate spots for assessing differential expression in microarray experiments. Bioinformatics. 2005; 21(9):2067-75. DOI: 10.1093/bioinformatics/bti270. View

Selinger C, Tisoncik-Go J, Menachery V, Agnihothram S, Law G, Chang J . Cytokine systems approach demonstrates differences in innate and pro-inflammatory host responses between genetically distinct MERS-CoV isolates. BMC Genomics. 2014; 15:1161. PMC: 4522970. DOI: 10.1186/1471-2164-15-1161. View

Matsuyama S, Nao N, Shirato K, Kawase M, Saito S, Takayama I . Enhanced isolation of SARS-CoV-2 by TMPRSS2-expressing cells. Proc Natl Acad Sci U S A. 2020; 117(13):7001-7003. PMC: 7132130. DOI: 10.1073/pnas.2002589117. View

Lanczky A, Nagy A, Bottai G, Munkacsy G, Szabo A, Santarpia L . miRpower: a web-tool to validate survival-associated miRNAs utilizing expression data from 2178 breast cancer patients. Breast Cancer Res Treat. 2016; 160(3):439-446. DOI: 10.1007/s10549-016-4013-7. View

. The Genotype-Tissue Expression (GTEx) project. Nat Genet. 2013; 45(6):580-5. PMC: 4010069. DOI: 10.1038/ng.2653. View

10.

Cunha G . Mesenchymal-epithelial interactions: past, present, and future. Differentiation. 2008; 76(6):578-86. DOI: 10.1111/j.1432-0436.2008.00290.x. View

11.

DeDiego M, Nieto-Torres J, Jimenez-Guardeno J, Regla-Nava J, Alvarez E, Oliveros J . Severe acute respiratory syndrome coronavirus envelope protein regulates cell stress response and apoptosis. PLoS Pathog. 2011; 7(10):e1002315. PMC: 3197621. DOI: 10.1371/journal.ppat.1002315. View

12.

Vaarala M, Porvari K, Kellokumpu S, Kyllonen A, Vihko P . Expression of transmembrane serine protease TMPRSS2 in mouse and human tissues. J Pathol. 2001; 193(1):134-40. DOI: 10.1002/1096-9896(2000)9999:9999<::AID-PATH743>3.0.CO;2-T. View

13.

Hoffmann M, Kleine-Weber H, Schroeder S, Kruger N, Herrler T, Erichsen S . SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020; 181(2):271-280.e8. PMC: 7102627. DOI: 10.1016/j.cell.2020.02.052. View

14.

Rubin M, Chinnaiyan A . Bioinformatics approach leads to the discovery of the TMPRSS2:ETS gene fusion in prostate cancer. Lab Invest. 2006; 86(11):1099-102. DOI: 10.1038/labinvest.3700477. View

15.

Strope J, PharmD C, Figg W . TMPRSS2: Potential Biomarker for COVID-19 Outcomes. J Clin Pharmacol. 2020; 60(7):801-807. PMC: 7280622. DOI: 10.1002/jcph.1641. View

16.

Addeo A, Friedlaender A . Cancer and COVID-19: Unmasking their ties. Cancer Treat Rev. 2020; 88:102041. PMC: 7831797. DOI: 10.1016/j.ctrv.2020.102041. View

17.

Zhou P, Yang X, Wang X, Hu B, Zhang L, Zhang W . A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020; 579(7798):270-273. PMC: 7095418. DOI: 10.1038/s41586-020-2012-7. View

18.

Paoloni-Giacobino A, Chen H, Peitsch M, Rossier C, Antonarakis S . Cloning of the TMPRSS2 gene, which encodes a novel serine protease with transmembrane, LDLRA, and SRCR domains and maps to 21q22.3. Genomics. 1997; 44(3):309-20. DOI: 10.1006/geno.1997.4845. View

19.

Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z . GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 2017; 45(W1):W98-W102. PMC: 5570223. DOI: 10.1093/nar/gkx247. View

20.

Wallace T, Prueitt R, Yi M, Howe T, Gillespie J, Yfantis H . Tumor immunobiological differences in prostate cancer between African-American and European-American men. Cancer Res. 2008; 68(3):927-36. DOI: 10.1158/0008-5472.CAN-07-2608. View